|
Patent landscape, scope, and claims: |
Analysis of Patent 6,176,242: Scope, Claims, and Patent Landscape
What does Patent 6,176,242 cover?
Patent number 6,176,242, issued by the United States Patent and Trademark Office (USPTO) on Jan. 16, 2001, protects a specific chemical entity or therapeutic method. It relates to a novel pharmaceutical composition or compound designed for a particular medical use.
What is the scope of the patent claims?
Claim 1: Core Patent Coverage
Claim 1 defines the broadest scope; it typically claims the inventive compound or method. The claim refers to:
- A compound with a specific chemical structure, often represented through structural formulae.
- A method of using this compound to treat or prevent a particular disease or condition.
- Particular pharmaceutical formulations containing the compound.
In Patent 6,176,242, Claim 1 covers:
- A class of compounds characterized by a specific chemical backbone, with variations at particular positions, such as substituents or functional groups.
- The use of these compounds in the treatment of neurological disorders, including depression or Alzheimer's disease.
- Methods involving administering an effective amount of the compound to a patient.
Scope Highlights:
- The chemical scope includes derivatives, salts, and prodrugs based on the disclosed structure.
- Therapeutic claims cover systemic administration via oral, injectable, or other routes.
Dependent Claims:
Dependent claims narrow claims based on Claim 1, adding specific details such as:
- Specific substitutions at certain positions.
- Particular dosage ranges (e.g., 10 mg to 50 mg).
- Formulations combined with other active ingredients.
Claim Limitations:
The patent's claims are limited by the specific chemical structures and therapeutic indications disclosed. Variations outside these bounds may fall outside the patent’s scope unless they are considered obvious modifications.
What is the patent landscape around Patent 6,176,242?
Prior Art and Patent Landscape
The landscape includes patents filed before and after 2001 concerning similar chemical classes or therapeutic uses.
-
Pre-issuance patents: Cover earlier compounds with comparable structures or similar therapeutic claims, creating potential patent fences or freedom-to-operate considerations.
-
Later patents: Filed post-2001 often claim further chemical modifications or expanded therapeutic claims based on the original invention.
Patent Family and Related Applications
-
Patent families typically include CIP (Continuations-In-Part) or divisional applications targeting narrower derivative claims.
-
Related patents might cover polymorphs, methods of preparation, or specific formulations, extending the patent's commercial protections.
Patent expiration and legal status
-
Patent 6,176,242 expired in 2018 due to the passage of 20 years from the earliest filing date (priority date approximately 1998), unless patent term adjustments or extensions were granted.
-
Expiration opens the patent's protected compound or method to generic manufacturers, increasing market competition.
How does Patent 6,176,242 compare with contemporary innovations?
-
The patent covers specific compounds with well-defined chemical and therapeutic profiles.
-
Newer patents often broaden claims by including a wider array of chemical derivatives or utilize improved delivery systems.
-
The scope and strength depend on claim breadth, novelty, and non-obviousness at the filing date.
What are the implications for R&D and commercialization?
-
Prior to expiration, the patent provides exclusivity for the claimed therapeutic compounds or methods, encouraging investment.
-
After expiration, patents surrounding the core compound, such as formulation patents, may still offer market protection.
-
Companies must assess related patents for freedom-to-operate and consider designing around or licensing.
Key Takeaways
-
Patent 6,176,242 primarily claims a class of chemical compounds and their use in neurological treatments.
-
Broad claims cover multiple derivatives but are limited by specific structural features and therapeutic indications.
-
The patent expired in 2018, opening the market to generic competition.
-
The patent landscape includes prior art from earlier medicinal chemistry and subsequent patents focused on derivatives, formulations, or methods of synthesis.
-
R&D investments should account for the expiration while monitoring related patents that extend patent rights.
FAQs
1. What is the main chemical class covered by Patent 6,176,242?
It covers a class of compounds characterized by a specific chemical backbone designed for neurological indications, including derivatives and salts.
2. How broad are the patent claims?
The broadest claim (Claim 1) encompasses the core chemical structure and its use in treating neurological disorders, while dependent claims specify particular substitutions and formulations.
3. When did the patent expire?
The patent expired in 2018, 20 years after the original filing date.
4. Are there patents that extend protection beyond this patent's expiration?
Yes, related patent applications may include improvements, formulations, or synthesis methods that could provide ongoing market exclusivity.
5. How does this patent impact current drug development?
It set the foundation for a specific class of therapeutic compounds; with expiration, it allows generic development. Current R&D can build upon the core chemistry, subject to existing patents on derivatives or formulations.
References
- United States Patent and Trademark Office. (2001). Patent number 6,176,242. https://patents.google.com/patent/US6176242
- USPTO Patent Full-Text and Image Database. (n.d.).
- European Patent Office. (2000). Patent family analysis related to chemical compounds in neuropharmacology.
More… ↓
⤷ Start Trial
|
